Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis
Crossref DOI link: https://doi.org/10.1007/s41669-017-0054-z
Published Online: 2017-08-29
Published Print: 2018-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Michaud, Tzeyu L. http://orcid.org/0000-0002-2053-3942
Kane, Robert L.
McCarten, J. Riley
Gaugler, Joseph E.
Nyman, John A.
Kuntz, Karen M.
License valid from 2017-08-29